Abstract: Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.

Abstract: An integrated circuit comprising voltage modulation circuitry arranged to convert an input voltage level at an input node to an output voltage level at an output node. The voltage modulation circuitry comprises a switching element arranged to connect the input node to the output node when in an ON condition, and switching control module operably coupled to the switching element and arranged to control the connection of the input node to the output node by the switching element in accordance with a switching frequency. The voltage modulation circuitry further comprises frequency control module operably coupled to the switching control module and arranged to receive an indication of the input voltage level at the input node, and to configure the switching frequency based at least partly on the input voltage level indication.

Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.

Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.

Abstract: The present teachings are directed toward electrocatalyst compositions of platinum, titanium and at least a third metal for use in fuel cells. The electrocatalyst composition is composed essentially of platinum present in an atomic percentage ranging between about 55 percent and about 85 percent, titanium present in an atomic percentage ranging between about 1 percent and about 30 percent, and at least a third metal present in an atomic percentage ranging between about 1 percent and about 30 percent. The third metal can be at least one member selected from the group consisting of nickel, vanadium and molybdenum.

Abstract: The present teachings are directed toward electrocatalyst compositions of platinum, tungsten and at least a third metal for use in fuel cells. The electrocatalyst composition is composed essentially of platinum present in an atomic percentage ranging between about 20 percent and about 55 percent, tungsten present in an atomic percentage ranging between about 30 percent and about 75 percent, and at least a third metal present in an atomic percentage ranging between about 1 percent and about 40 percent. The third metal can be at least one member selected from the group consisting of scandium, vanadium, chromium, manganese, iron, cobalt, copper, zinc, yttrium, niobium, molybdenum, cadmium, tin, hafnium, tantalum and rhenium; additional fourth and fifth metals can also be present.

Abstract: The present teachings are directed toward electrocatalyst composition of an alloy of platinum and tungsten for use in fuel cells. The alloy consists essentially of platinum metal present in an atomic percentage ranging between about 20 percent and about 50 percent, and tungsten metal present in an atomic percentage ranging between about 50 percent and about 80 percent.

Abstract: The present teachings are directed toward electrocatalyst compositions of platinum, titanium and at least a third metal for use in fuel cells. The electrocatalyst composition is composed essentially of platinum present in an atomic percentage ranging between about 50 percent and about 85 percent, titanium present in an atomic percentage ranging between about 5 percent and about 30 percent, and at least a third metal present in an atomic percentage ranging between about 1 percent and about 30 percent. The third metal can be at least one member selected from the group consisting of cobalt, ruthenium, rhodium, palladium, silver, osmium, iridium and gold.

Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.

Abstract: The present teachings are directed toward electrocatalyst compositions of alloys of platinum, tungsten and nickel for use in fuel cells. The alloys consists essentially of platinum present in an atomic percentage ranging between about 20 percent and about 45 percent, tungsten present in an atomic percentage ranging between about 30 percent and about 70 percent, and nickel present in an atomic percentage ranging between about 5 percent and about 25 percent.

Abstract: The present teachings are directed toward electrocatalyst compositions of platinum, titanium and at least a third metal for use in fuel cells. The electrocatalyst composition is composed essentially of platinum present in an atomic percentage ranging between about 55 percent and about 95 percent, titanium present in an atomic percentage ranging between about 1 percent and about 30 percent, and at least a third metal present in an atomic percentage ranging between about 1 percent and about 30 percent. The third metal can be at least one member selected from the group consisting of copper, manganese and iron.

Abstract: Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF? and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive.

Abstract: A voltage regulation apparatus comprises a plurality of individually switchable current sources coupled to an output for coupling the voltage regulation apparatus to an external load. The output is monitored using a bridge divider and a comparator. The bridge divider generates a feedback voltage, that is compared with a reference voltage, representative of a target voltage to be maintained at the output, when loaded. A digital sequencer unit is coupled to the comparator and responds to the comparator to increase or decrease a number of the plurality of individually switchable current sources activated, thereby causing a collective current generated by the activated number of the plurality of individually switchable current sources to converge on a load current, demanded by the external load.

Abstract: A data communication system includes one or more data processing units and includes a central control unit. The decentralized data processing units are connected to the central control unit by data connection. The central control unit includes a synchronisation unit for outputting via the data connection an electric synchronisation signal to the data processing unit. The data processing unit includes a data generator for generating data and transmitting, after the electric synchronisation signal, data to the central control unit. The central control unit further includes a discharge signal generator for outputting a discharge signal via the data connection to the data processing unit.

Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.

Abstract: An electrostatic discharge protection apparatus comprises a stack arrangement having a first electrostatic discharge protection element and a second electrostatic discharge protection element. The stack arrangement is arranged to provide a bias potential between the first and second electrostatic discharge protection elements. In one embodiment, the bias potential can be achieved by a clamp arrangement coupled across the stack arrangement.

Abstract: The present application is directed to a fabrication method to reduce Pt loading in fuel cells through the use of thin film electrodes by increasing Pt utilization and the use of more active Pt alloys that can be easily and inexpensively fabricated by sputter deposition. Pt and Pt alloy thin films were sputter deposited onto carbon/Nafion® decals and subsequently hot pressed with the catalyst thin film towards the membrane. The results show improved mass performance and catalyst utilization with Pt thin films and increased mass activities can be achieved with PtCo (76:24 atomic ratio) and PtCr (80:20 atomic ratio) as compared to pure Pt. Mass activity improvements of 14 mV and 8 mV were observed for the PtCo and PtCr alloys with respect to a pure Pt film with similar mass loading under 300/350 kPa hydrogen/oxygen operation.

Abstract: The present teachings are directed toward electrocatalyst compositions of alloys of platinum, tungsten and nickel for use in fuel cells. The alloys consists essentially of platinum present in an atomic percentage ranging between about 20 percent and about 45 percent, tungsten present in an atomic percentage ranging between about 30 percent and about 70 percent, and nickel present in an atomic percentage ranging between about 5 percent and about 25 percent.

Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

Abstract: The present teachings are directed toward electrocatalyst compositions of alloys of platinum, tungsten and one of either of nickel or zirconium for use in fuel cells. The alloys consists essentially of platinum present in an atomic percentage ranging between about 20 percent and about 45 percent, tungsten present in an atomic percentage ranging between about 30 percent and about 70 percent, and one of either nickel present in an atomic percentage ranging between about 5 percent and about 25 percent, or zirconium present in an atomic percentage ranging between about 5 percent and about 40 percent.